GERN
NASDAQ · Biotechnology
Geron Corp
$0.89
-0.05 (-5.47%)
Open$0.93
Previous Close$0.95
Day High$0.94
Day Low$0.86
52W High$2.01
52W Low$0.84
Volume—
Avg Volume17.16M
Market Cap585.16M
P/E Ratio—
EPS$-0.10
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+2,025.4% upside
Current
$0.89
$0.89
Target
$19.01
$19.01
$12.94
$19.01 avg
$24.33
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 170.56M | 153.95M | 141.15M |
| Net Income | -77,490,125 | -36,660,557 | -32,364,939 |
| Profit Margin | -45.4% | -23.8% | -22.9% |
| EBITDA | -63,204,236 | -44,322,691 | -40,350,825 |
| Free Cash Flow | — | -25,979,960 | -28,291,864 |
| Rev Growth | +574.2% | +15.1% | +6.9% |
| Debt/Equity | 1.10 | 0.42 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |